Rupatadine in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled multicentre study
| Autor: | S. Ianosi, A. Kaszuba, A. Malbran, I. Izquierdo, G. Poop, Ramon M. Pujol, Ana Giménez-Arnau, I. Perez, E. Donado, E. Arnaiz |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Adult
Male medicine.medical_specialty Allergy Randomization Adolescent Urticaria Immunology Rupatadine Cyproheptadine Placebo law.invention Double-Blind Method Randomized controlled trial law Internal medicine Immunopathology medicine Humans Immunology and Allergy Child Adverse effect Aged business.industry Dermatology Life Quality Index Middle Aged medicine.disease Surgery Treatment Outcome Chronic Disease Female business medicine.drug |
| Zdroj: | Allergy. 62:539-546 |
| ISSN: | 1398-9995 0105-4538 |
| DOI: | 10.1111/j.1398-9995.2007.01330.x |
| Popis: | Background: Chronic urticaria is one of the most common and disturbing cutaneous condition. The treatment of chronic idiopathic urticaria (CIU) is still a challenge. Antihistamines are recommended as first-line treatment. Rupatadine is a new potent nonsedative anti-H1. Objective: To study rupatadine efficacy and safety for moderate to severe CIU treatment. Methods: This randomized, double-blind, placebo-controlled, parallel-group, multicentre, study was designed to assess primarily mean pruritus score (MPS) reduction with rupatadine, 10 and 20 mg, administered once daily for 4 weeks. Three hundred and thirty-three patients with active episodes of moderate-to-severe CIU were included. Results: A 57.5% (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text